Concepts (215)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
---|
AIDS Vaccines | 15 | 2023 | 895 | 3.230 |
Why?
|
Viral Vaccines | 8 | 2023 | 596 | 2.160 |
Why?
|
HIV-1 | 23 | 2024 | 6850 | 2.120 |
Why?
|
Chikungunya virus | 3 | 2023 | 53 | 1.840 |
Why?
|
Antibodies, Neutralizing | 15 | 2024 | 1931 | 1.560 |
Why?
|
HIV Antibodies | 13 | 2024 | 1300 | 1.390 |
Why?
|
Immunity, Cellular | 9 | 2021 | 1557 | 1.220 |
Why?
|
Antibodies, Viral | 11 | 2022 | 3146 | 1.090 |
Why?
|
HIV Infections | 21 | 2024 | 17270 | 1.060 |
Why?
|
Macaca mulatta | 12 | 2020 | 2316 | 1.010 |
Why?
|
env Gene Products, Human Immunodeficiency Virus | 6 | 2020 | 368 | 0.950 |
Why?
|
Vaccines, Inactivated | 3 | 2020 | 179 | 0.750 |
Why?
|
Epitopes | 4 | 2019 | 2502 | 0.580 |
Why?
|
HIV Envelope Protein gp120 | 3 | 2021 | 914 | 0.550 |
Why?
|
Adenoviridae | 7 | 2021 | 1084 | 0.500 |
Why?
|
SAIDS Vaccines | 2 | 2016 | 144 | 0.500 |
Why?
|
Adjuvants, Immunologic | 1 | 2020 | 1036 | 0.470 |
Why?
|
Adenoviruses, Human | 2 | 2015 | 255 | 0.460 |
Why?
|
Simian immunodeficiency virus | 3 | 2016 | 805 | 0.450 |
Why?
|
Antigens, Viral | 2 | 2018 | 980 | 0.430 |
Why?
|
Otolaryngology | 1 | 2020 | 685 | 0.430 |
Why?
|
Viral Envelope Proteins | 2 | 2016 | 638 | 0.430 |
Why?
|
Occupational Diseases | 1 | 2020 | 1487 | 0.400 |
Why?
|
Adenovirus Infections, Human | 1 | 2012 | 73 | 0.390 |
Why?
|
Host-Pathogen Interactions | 1 | 2020 | 1442 | 0.380 |
Why?
|
Genetic Vectors | 9 | 2023 | 3379 | 0.380 |
Why?
|
Immunity, Humoral | 5 | 2021 | 602 | 0.370 |
Why?
|
Antiviral Agents | 2 | 2022 | 3055 | 0.340 |
Why?
|
Occupational Exposure | 1 | 2020 | 1810 | 0.340 |
Why?
|
Acquired Immunodeficiency Syndrome | 1 | 2018 | 2198 | 0.340 |
Why?
|
Immunization Schedule | 2 | 2020 | 223 | 0.320 |
Why?
|
Peptide Fragments | 3 | 2021 | 5095 | 0.310 |
Why?
|
Double-Blind Method | 8 | 2021 | 12261 | 0.280 |
Why?
|
Vaccination | 7 | 2024 | 3354 | 0.260 |
Why?
|
Simian Acquired Immunodeficiency Syndrome | 3 | 2016 | 538 | 0.260 |
Why?
|
Antibodies, Monoclonal | 5 | 2023 | 9163 | 0.240 |
Why?
|
Viral Load | 4 | 2021 | 3321 | 0.240 |
Why?
|
Riots | 1 | 2004 | 4 | 0.230 |
Why?
|
Hospitals, State | 1 | 2004 | 28 | 0.230 |
Why?
|
Virus Replication | 3 | 2018 | 2430 | 0.220 |
Why?
|
CD8-Positive T-Lymphocytes | 3 | 2021 | 4550 | 0.210 |
Why?
|
Coronavirus Infections | 1 | 2020 | 3077 | 0.210 |
Why?
|
Peptides | 1 | 2014 | 4338 | 0.210 |
Why?
|
Pneumonia, Viral | 1 | 2020 | 3197 | 0.200 |
Why?
|
Fires | 1 | 2004 | 169 | 0.200 |
Why?
|
Aedes | 1 | 2023 | 97 | 0.200 |
Why?
|
Vaccines, Attenuated | 1 | 2023 | 314 | 0.200 |
Why?
|
Quarantine | 1 | 2004 | 176 | 0.190 |
Why?
|
Young Adult | 12 | 2024 | 58755 | 0.190 |
Why?
|
Injections, Intramuscular | 2 | 2020 | 553 | 0.180 |
Why?
|
Guinea Pigs | 3 | 2019 | 1317 | 0.180 |
Why?
|
Humans | 47 | 2024 | 757566 | 0.170 |
Why?
|
Placebos | 2 | 2021 | 1661 | 0.170 |
Why?
|
Adult | 21 | 2024 | 219725 | 0.160 |
Why?
|
Immunization, Secondary | 2 | 2018 | 368 | 0.160 |
Why?
|
Purpura Fulminans | 1 | 2018 | 21 | 0.160 |
Why?
|
Animals | 21 | 2023 | 167718 | 0.160 |
Why?
|
Vaccinia virus | 2 | 2018 | 331 | 0.160 |
Why?
|
Protein C | 1 | 2018 | 133 | 0.150 |
Why?
|
HIV Envelope Protein gp160 | 1 | 2018 | 92 | 0.150 |
Why?
|
Clinical Trials as Topic | 4 | 2020 | 7982 | 0.150 |
Why?
|
Thrombomodulin | 1 | 2018 | 105 | 0.150 |
Why?
|
Thrombosis | 2 | 2023 | 2931 | 0.150 |
Why?
|
AIDS-Related Opportunistic Infections | 2 | 1999 | 662 | 0.150 |
Why?
|
Immunization, Passive | 1 | 2020 | 616 | 0.150 |
Why?
|
Immunoglobulin G | 3 | 2020 | 4540 | 0.140 |
Why?
|
Dengue | 1 | 2020 | 254 | 0.140 |
Why?
|
HIV Seropositivity | 1 | 2022 | 960 | 0.140 |
Why?
|
Thrombocytopenia | 1 | 2023 | 1174 | 0.130 |
Why?
|
Post-Exposure Prophylaxis | 1 | 2016 | 108 | 0.130 |
Why?
|
Toll-Like Receptor 7 | 1 | 2016 | 177 | 0.130 |
Why?
|
Middle Aged | 13 | 2023 | 219192 | 0.120 |
Why?
|
Vaccines, DNA | 1 | 2016 | 286 | 0.120 |
Why?
|
Immunoglobulin A | 1 | 2018 | 979 | 0.120 |
Why?
|
Withholding Treatment | 1 | 2019 | 611 | 0.120 |
Why?
|
Structure-Activity Relationship | 1 | 2020 | 3069 | 0.120 |
Why?
|
Vaccines, Synthetic | 2 | 2018 | 617 | 0.120 |
Why?
|
RNA, Viral | 2 | 2020 | 2837 | 0.120 |
Why?
|
Workplace | 1 | 2020 | 856 | 0.110 |
Why?
|
Serum | 1 | 2014 | 210 | 0.110 |
Why?
|
Female | 22 | 2024 | 389943 | 0.110 |
Why?
|
Antiretroviral Therapy, Highly Active | 1 | 2021 | 1896 | 0.110 |
Why?
|
pol Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 39 | 0.110 |
Why?
|
Male | 18 | 2024 | 358180 | 0.100 |
Why?
|
Viral Proteins | 1 | 2020 | 1803 | 0.100 |
Why?
|
Drug Carriers | 2 | 2018 | 705 | 0.100 |
Why?
|
Vascular Diseases | 1 | 2020 | 1160 | 0.100 |
Why?
|
Anti-Retroviral Agents | 2 | 2019 | 1780 | 0.100 |
Why?
|
CD4-Positive T-Lymphocytes | 2 | 2021 | 4350 | 0.100 |
Why?
|
Viremia | 3 | 2022 | 706 | 0.100 |
Why?
|
Gene Products, gag | 1 | 2012 | 312 | 0.100 |
Why?
|
gag Gene Products, Human Immunodeficiency Virus | 1 | 2012 | 206 | 0.100 |
Why?
|
Disease Transmission, Infectious | 1 | 2016 | 557 | 0.090 |
Why?
|
Tissue Donors | 1 | 2020 | 2311 | 0.090 |
Why?
|
Vaccines | 1 | 2019 | 832 | 0.090 |
Why?
|
Pregnancy Complications, Infectious | 1 | 2021 | 2125 | 0.080 |
Why?
|
Disease Management | 1 | 2020 | 2495 | 0.080 |
Why?
|
Self Report | 1 | 2020 | 3709 | 0.080 |
Why?
|
Inhibitory Concentration 50 | 2 | 2020 | 462 | 0.080 |
Why?
|
Epitopes, T-Lymphocyte | 1 | 2012 | 823 | 0.080 |
Why?
|
Self Medication | 1 | 2009 | 117 | 0.080 |
Why?
|
Thyrotoxicosis | 1 | 2009 | 85 | 0.080 |
Why?
|
Homosexuality, Male | 1 | 2016 | 1330 | 0.080 |
Why?
|
T-Lymphocytes | 3 | 2021 | 10167 | 0.070 |
Why?
|
Binding Sites | 1 | 2016 | 6034 | 0.070 |
Why?
|
Immunotherapy, Adoptive | 1 | 2016 | 1454 | 0.070 |
Why?
|
Thyroid Hormones | 1 | 2009 | 404 | 0.070 |
Why?
|
Models, Animal | 1 | 2012 | 2110 | 0.060 |
Why?
|
Genetic Variation | 1 | 2020 | 6549 | 0.060 |
Why?
|
Firesetting Behavior | 1 | 2004 | 5 | 0.060 |
Why?
|
Registries | 1 | 2020 | 8164 | 0.060 |
Why?
|
Pandemics | 2 | 2022 | 8600 | 0.060 |
Why?
|
Anorexia | 1 | 2004 | 154 | 0.060 |
Why?
|
Adolescent | 6 | 2024 | 87819 | 0.060 |
Why?
|
Intestinal Mucosa | 1 | 2014 | 3021 | 0.050 |
Why?
|
Community-Institutional Relations | 1 | 2004 | 206 | 0.050 |
Why?
|
Incidence | 1 | 2020 | 21217 | 0.050 |
Why?
|
Compassionate Use Trials | 1 | 2021 | 50 | 0.050 |
Why?
|
Bulimia | 1 | 2004 | 400 | 0.050 |
Why?
|
Antibody Formation | 2 | 2019 | 1397 | 0.050 |
Why?
|
Health Knowledge, Attitudes, Practice | 1 | 2016 | 3970 | 0.050 |
Why?
|
Prescription Drugs | 1 | 2009 | 626 | 0.050 |
Why?
|
Randomized Controlled Trials as Topic | 1 | 2018 | 10135 | 0.050 |
Why?
|
New York City | 1 | 2004 | 726 | 0.050 |
Why?
|
History, 19th Century | 1 | 2004 | 720 | 0.050 |
Why?
|
Emigration and Immigration | 1 | 2004 | 394 | 0.050 |
Why?
|
Time Factors | 2 | 2020 | 39811 | 0.050 |
Why?
|
Hospitalization | 1 | 2020 | 10634 | 0.040 |
Why?
|
Bronchoalveolar Lavage | 1 | 2020 | 128 | 0.040 |
Why?
|
Adenosine Monophosphate | 1 | 2021 | 228 | 0.040 |
Why?
|
Flavivirus | 1 | 2020 | 22 | 0.040 |
Why?
|
Mice, Inbred BALB C | 2 | 2020 | 6204 | 0.040 |
Why?
|
Capnocytophaga | 1 | 2018 | 26 | 0.040 |
Why?
|
Alanine | 1 | 2021 | 603 | 0.040 |
Why?
|
Epitope Mapping | 1 | 2020 | 297 | 0.040 |
Why?
|
Vero Cells | 1 | 2020 | 482 | 0.040 |
Why?
|
Complement Activation | 1 | 2020 | 446 | 0.040 |
Why?
|
DNA, Viral | 2 | 2016 | 2195 | 0.040 |
Why?
|
Vaccines, Subunit | 1 | 2018 | 161 | 0.040 |
Why?
|
Dengue Virus | 1 | 2020 | 200 | 0.040 |
Why?
|
Cross Reactions | 1 | 2020 | 818 | 0.040 |
Why?
|
Ventricular Dysfunction, Left | 1 | 2009 | 2115 | 0.040 |
Why?
|
Glycosylation | 1 | 2020 | 1096 | 0.040 |
Why?
|
Syndrome | 1 | 2023 | 3261 | 0.040 |
Why?
|
Longitudinal Studies | 3 | 2018 | 14473 | 0.040 |
Why?
|
Pancreatitis | 1 | 2004 | 1096 | 0.040 |
Why?
|
Protein Binding | 2 | 2020 | 9312 | 0.040 |
Why?
|
Platelet Activation | 1 | 2020 | 645 | 0.030 |
Why?
|
Polysaccharides | 1 | 2023 | 1007 | 0.030 |
Why?
|
Pregnant Women | 1 | 2021 | 561 | 0.030 |
Why?
|
Aspartate Aminotransferases | 1 | 2018 | 415 | 0.030 |
Why?
|
E-Selectin | 1 | 2018 | 576 | 0.030 |
Why?
|
British Columbia | 1 | 2016 | 240 | 0.030 |
Why?
|
Endothelium | 1 | 2018 | 764 | 0.030 |
Why?
|
Dizziness | 1 | 2018 | 257 | 0.030 |
Why?
|
Puerto Rico | 1 | 2016 | 373 | 0.030 |
Why?
|
Sarcoma, Kaposi | 1 | 1998 | 374 | 0.030 |
Why?
|
CD4 Lymphocyte Count | 1 | 2021 | 2569 | 0.030 |
Why?
|
RNA, Ribosomal, 16S | 1 | 2018 | 1005 | 0.030 |
Why?
|
Immunization | 1 | 2019 | 1226 | 0.030 |
Why?
|
Back Pain | 1 | 2018 | 543 | 0.030 |
Why?
|
Case-Control Studies | 1 | 2012 | 22022 | 0.030 |
Why?
|
Clinical Trials, Phase I as Topic | 1 | 2015 | 326 | 0.030 |
Why?
|
United States | 4 | 2024 | 71902 | 0.030 |
Why?
|
Adoptive Transfer | 1 | 2016 | 819 | 0.030 |
Why?
|
Human Immunodeficiency Virus Proteins | 1 | 2013 | 59 | 0.030 |
Why?
|
Specific Pathogen-Free Organisms | 1 | 2013 | 219 | 0.030 |
Why?
|
Pregnancy | 3 | 2021 | 29712 | 0.030 |
Why?
|
Immunoglobulins | 1 | 2016 | 859 | 0.030 |
Why?
|
HIV Antigens | 1 | 2013 | 325 | 0.030 |
Why?
|
Mutagenesis, Insertional | 1 | 2015 | 656 | 0.030 |
Why?
|
Brazil | 1 | 2016 | 1217 | 0.030 |
Why?
|
Substance-Related Disorders | 1 | 2009 | 4404 | 0.020 |
Why?
|
Models, Theoretical | 1 | 2024 | 3560 | 0.020 |
Why?
|
Mice | 4 | 2021 | 81066 | 0.020 |
Why?
|
Abdominal Pain | 1 | 2018 | 1064 | 0.020 |
Why?
|
Drug Therapy, Combination | 2 | 1999 | 6292 | 0.020 |
Why?
|
Diarrhea | 1 | 2018 | 1317 | 0.020 |
Why?
|
Aged | 2 | 2022 | 167890 | 0.020 |
Why?
|
Quality of Life | 2 | 2023 | 13263 | 0.020 |
Why?
|
Fatigue | 1 | 2018 | 1545 | 0.020 |
Why?
|
Proteomics | 1 | 2023 | 3809 | 0.020 |
Why?
|
Rectum | 1 | 2014 | 891 | 0.020 |
Why?
|
HEK293 Cells | 1 | 2019 | 4257 | 0.020 |
Why?
|
C-Reactive Protein | 1 | 2020 | 3809 | 0.020 |
Why?
|
Models, Molecular | 1 | 2019 | 5406 | 0.020 |
Why?
|
Amino Acid Sequence | 1 | 2019 | 13442 | 0.020 |
Why?
|
Patient Selection | 1 | 1998 | 4235 | 0.020 |
Why?
|
Dose-Response Relationship, Drug | 1 | 2018 | 10749 | 0.020 |
Why?
|
Macrophages | 1 | 2020 | 5732 | 0.020 |
Why?
|
Cytokines | 1 | 2020 | 7336 | 0.020 |
Why?
|
Immunity, Innate | 1 | 2016 | 3043 | 0.010 |
Why?
|
Aging | 1 | 2022 | 8654 | 0.010 |
Why?
|
Anticoagulants | 1 | 2018 | 4777 | 0.010 |
Why?
|
Anti-HIV Agents | 1 | 1999 | 4502 | 0.010 |
Why?
|
Gene Expression | 1 | 2015 | 7584 | 0.010 |
Why?
|
Primary Health Care | 1 | 1999 | 4652 | 0.010 |
Why?
|
Lung | 1 | 2020 | 9973 | 0.010 |
Why?
|
Mice, Inbred C57BL | 1 | 2020 | 21990 | 0.010 |
Why?
|
Molecular Sequence Data | 1 | 2013 | 17615 | 0.010 |
Why?
|
Inflammation | 1 | 2020 | 10709 | 0.010 |
Why?
|
Follow-Up Studies | 1 | 2021 | 39020 | 0.010 |
Why?
|
Infant | 1 | 2021 | 36045 | 0.010 |
Why?
|
Disease Models, Animal | 1 | 2019 | 18114 | 0.010 |
Why?
|
Cohort Studies | 1 | 2021 | 41190 | 0.010 |
Why?
|
Internet | 1 | 2009 | 3081 | 0.010 |
Why?
|
Family Practice | 1 | 1999 | 509 | 0.010 |
Why?
|
Aged, 80 and over | 1 | 2020 | 58558 | 0.010 |
Why?
|
Stroke Volume | 1 | 2009 | 5461 | 0.010 |
Why?
|
Mutation | 1 | 2019 | 29929 | 0.010 |
Why?
|
Recurrence | 1 | 2004 | 8426 | 0.010 |
Why?
|
Prospective Studies | 1 | 2016 | 54092 | 0.010 |
Why?
|
Treatment Outcome | 1 | 2018 | 64242 | 0.010 |
Why?
|
Health Care Surveys | 1 | 1999 | 2425 | 0.010 |
Why?
|
Child | 1 | 1998 | 79782 | 0.010 |
Why?
|
Concepts
(215)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(49)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_
Physical Neighbors
People whose addresses are nearby this person.
_